Adunolimab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adunolimab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adunolimab Today - Breaking & Trending Today

Cantargia publishes ASCO 2023 poster on promising nadunolimab efficacy in non-small cell lung cancer

Cantargia today presented interim efficacy data for 39 non-small cell lung cancer patients treated with nadunolimab and platinum-based chemotherapy as a poster at the ASCO Annual Meeting 2023 , and. | June 4, 2023 ....

Luis Paz , Non Small Cell , Cantargia Ab Publ Stock Exchange , Press Release , 023 Canta Se0006371126 ,

Cantargia AB: Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023

LUND, Sweden, April 4, 2023 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day focusing on new clinical results and biomarker data for ....

Region Flamande , David Liberg , Van Cutsem , Dominique Tersago , Eric Van Cutsem , Prnewswire Cantargia , University Hospitals Gasthuisberg , Vp Research , University Of Warsaw , Belgian Foundation , Nasdaq Stockholm , Division Head , Digestive Oncology , Eric Van , Medical University , Prof Van Cutsem , Belgian Royal Academy ,

Cantargia AB: Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer

LUND, Sweden, March 14, 2023 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported that two abstracts on its lead asset, the antibody nadunolimab (CAN04), have been ....

Dennis Riedl , Prnewswire Cantargia , Clinical Research Excluding Trials , Nasdaq Stockholm , Clinical Research Excluding , Therapeutic Benefit , Monday Apr , Wednesday Apr ,

Cantargia AB: Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer

LUND, Sweden, Feb. 23, 2023 /PRNewswire/ Cantargia (Cantargia AB) (NASDAQ Stockholm: CANTA) today reported favorable safety and promising early signs of efficacy following an initial analysis ....

Dennis Riedl , Durani Reynals , Agostina Stradella , Prnewswire Cantargia , Catalan Institute Of Oncology , Spanish Breast Cancer Group , Principal Investigator , Catalan Institute , Nasdaq Stockholm ,

Cantargia - New data support differentiation of nadunolimab

Cantargia has presented new data concerning its IL1RAP-targeting antibody, nadunolimab (CAN04), which demonstrates the drug's ability to reduce levels of tumour-promoting molecules in a pancreatic cancer ....

Kostenloser Wertpapierhandel ,